By Fineline Cube The CD19‑targeted genetically modified allogeneic chimeric antigen receptor T‑cell (CAR‑T) injection of Shanghai BRL Medicine, Inc. has been included in the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) pilot scheme encouraging the development of innovative drugs for rare diseases — the “Care Program‑Extension” — advancing a first‑of‑its‑kind cell therapy approach for relapsed/refractory systemic sclerosis (SSc).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | CDE, National Medical Products Administration (NMPA, China) |
| Designation | Inclusion in “Care Program‑Extension” — pilot scheme encouraging innovative drugs for rare diseases |
| Product | CD19‑targeted genetically modified allogeneic CAR‑T cell injection |
| Intended Indication | Relapsed/refractory systemic sclerosis (SSc) |
| Developer | Shanghai BRL Medicine, Inc. |
| Inclusion Date | 9 Sep 2026 (announced) |
| Development Stage / Next Steps | Not disclosed |
Product Profile & Platform Technology
- Modality: Allogeneic (universal) CAR‑T cell therapy — an off‑the‑shelf cell product derived from healthy donors rather than each patient’s own T cells, addressing the manufacturing time, cost and feasibility constraints of autologous CAR‑T.
- Target: CD19, the B‑cell surface antigen, directing CAR‑T‑mediated depletion of the autoreactive B cells implicated in SSc pathogenesis.
- Platform: Developed on BRL Medicine’s allogeneic universal CAR‑T platform, the company’s core technology for next‑generation off‑the‑shelf cell therapies.
- Differentiation: Applies CAR‑T technology — established in hematologic malignancies — to an autoimmune indication, part of a broader scientific movement exploring B‑cell‑directed cell therapy in severe autoimmune disease.
Disease Focus – Systemic Sclerosis (SSc)
- Condition: Systemic sclerosis (scleroderma) is a rare, chronic autoimmune disease characterized by fibrosis of the skin and internal organs, vasculopathy and immune dysregulation, with limited therapeutic options and significant morbidity.
- Unmet Need: Relapsed/refractory SSc patients — those failing existing immunosuppressive and antifibrotic therapies — represent the most challenging population, with few evidence‑based options and poor prognosis.
- Rationale for CD19 CAR‑T: Deep B‑cell depletion via CD19‑targeted CAR‑T offers a mechanistically distinct reset strategy for refractory autoimmunity; efficacy and safety data for BRL’s candidate were not disclosed in the announcement.
Market Impact & Outlook
- Rare Disease Policy Tailwind: Inclusion in the CDE’s “Care Program‑Extension” pilot signals regulatory encouragement for rare‑disease innovation in China, potentially offering BRL Medicine expedited interaction, technical support and development guidance under the scheme; specific incentives attached to the designation were not detailed.
- Off‑the‑Shelf Advantage: If successfully developed, an allogeneic universal CAR‑T could materially lower cost and expand access versus autologous products — a decisive factor in rare autoimmune diseases where patient numbers are small and dispersed.
- Autoimmune CAR‑T Frontier: BRL’s program positions the company at the intersection of two high‑momentum fields — universal cell therapy and autoimmune‑indication CAR‑T — where global competition is intensifying among biotechs and academic centers.
- Development Pathway: Clinical stage, trial design and timelines toward potential IND/filing milestones were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the development, regulatory pathway and potential clinical utility of BRL Medicine’s CD19‑targeted allogeneic CAR‑T therapy. Actual results may differ materially due to risks including preclinical and clinical outcomes, regulatory requirements, manufacturing scale‑up and competitive dynamics. Inclusion in a CDE pilot scheme does not guarantee subsequent approval.-Fineline Info & Tech